FDA Appeal In Zocor Case Could Open The Door For More Generics In The Fall
This article was originally published in The Pink Sheet Daily
FDA filed a notice of appeal challenging a court decision granting Ivax and Ranbaxy 180-day exclusivity for generic simvastatin.
You may also be interested in...
Teva and Ranbaxy appear slated for 180 days of simvastatin exclusivity after federal court ruling postponing mass generic entry into the sector until 2007.
A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.
The company is the latest big pharma to announce clinical trial delays due to the COVID-19 pandemic and has postponed an R&D day, but it also delivered the message that supply and commercial operations appear on track.